Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072150 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
A Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00072150 is a Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 99-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00072150, a Phase 2 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of the urothelium.
Conditions Studied
Interventions
- DRUG bortezomib
Study Locations (1)
California
- UCSF-Mount Zion - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072150
The ClinicalTrials.gov registry entry for NCT00072150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (60% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.
NCT00072150 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00072150 about?
NCT00072150 is a clinical study titled "Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma". Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of the urothelium.
What is the current status of trial NCT00072150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2003-10.
What conditions does trial NCT00072150 study?
This clinical trial studies the following conditions: Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Ureter Cancer, Stage III Bladder Cancer.
What interventions are being tested in trial NCT00072150?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00072150?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072150 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
COMPLETED · Phase 2
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
RECRUITING
-
Gene Therapy in Treating Patients With Advanced Bladder Cancer
COMPLETED · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Bladder Cancer
All registered trials for this condition
Transitional Cell Carcinoma of the Bladder
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.